Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Cell Interactions in Biliary Diseases: Clues from Pathophysiology and Repair Mechanisms to Foster Early Assessment.

Fabris L, Spirli C, Mertens J.

Int J Mol Sci. 2019 Aug 14;20(16). pii: E3961. doi: 10.3390/ijms20163961.

2.

Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.

Kyritsi K, Chen L, O'Brien A, Francis H, Hein TW, Venter J, Wu N, Ceci L, Zhou T, Zawieja D, Gashev AA, Meng F, Invernizzi P, Fabris L, Wu C, Skill NJ, Saxena R, Liangpunsakul S, Alpini G, Glaser S.

Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880. [Epub ahead of print]

PMID:
31344280
3.

Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis.

Kennedy L, Francis H, Invernizzi P, Venter J, Wu N, Carbone M, Gershwin ME, Bernuzzi F, Franchitto A, Alvaro D, Marzioni M, Onori P, Gaudio E, Sybenga A, Fabris L, Meng F, Glaser S, Alpini G.

FASEB J. 2019 Sep;33(9):10269-10279. doi: 10.1096/fj.201802606R. Epub 2019 Jun 28.

PMID:
31251081
4.

Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Fabris L, Fiorotto R, Spirli C, Cadamuro M, Mariotti V, Perugorria MJ, Banales JM, Strazzabosco M.

Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):497-511. doi: 10.1038/s41575-019-0156-4. Review.

5.

The tumour microenvironment and immune milieu of cholangiocarcinoma.

Fabris L, Perugorria MJ, Mertens J, Björkström NK, Cramer T, Lleo A, Solinas A, Sänger H, Lukacs-Kornek V, Moncsek A, Siebenhüner A, Strazzabosco M.

Liver Int. 2019 May;39 Suppl 1:63-78. doi: 10.1111/liv.14098. Review.

PMID:
30907492
6.

Pinealectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased melatonin synthesis.

Chen L, Zhou T, Wu N, O'Brien A, Venter J, Ceci L, Kyritsi K, Onori P, Gaudio E, Sybenga A, Xie L, Wu C, Fabris L, Invernizzi P, Zawieja D, Liangpunsakul S, Meng F, Francis H, Alpini G, Huang Q, Glaser S.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1525-1539. doi: 10.1016/j.bbadis.2019.03.002. Epub 2019 Mar 16.

PMID:
30890428
7.

Incretin-based treatment in type 2 diabetes mellitus and risk of cholangiocarcinoma: Is it only adverse drug effect?

Barbato GM, Cadamuro M, Fabris L.

Clin Res Hepatol Gastroenterol. 2019 Jun;43(3):232-235. doi: 10.1016/j.clinre.2019.01.009. Epub 2019 Mar 1. No abstract available.

PMID:
30833185
8.

Endo-laparoscopic reconstruction of the abdominal wall midline with linear stapler, the THT technique. Early results of the first case series.

Carrara A, Lauro E, Fabris L, Frisini M, Rizzo S.

Ann Med Surg (Lond). 2018 Dec 12;38:1-7. doi: 10.1016/j.amsu.2018.12.002. eCollection 2019 Feb.

9.

Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.

Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L.

J Hepatol. 2019 Apr;70(4):700-709. doi: 10.1016/j.jhep.2018.12.004. Epub 2018 Dec 14.

PMID:
30553841
10.

Animal models of cholestasis: An update on inflammatory cholangiopathies.

Mariotti V, Cadamuro M, Spirli C, Fiorotto R, Strazzabosco M, Fabris L.

Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):954-964. doi: 10.1016/j.bbadis.2018.07.025. Epub 2018 Aug 11. Review.

PMID:
30398152
11.

Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.

Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M.

Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):920-928. doi: 10.1016/j.bbadis.2018.08.038. Epub 2018 Sep 5. Review.

12.

Precision medicine in cholangiocarcinoma.

Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, Cillo U, Indraccolo S, Fabris L.

Transl Gastroenterol Hepatol. 2018 Jul 12;3:40. doi: 10.21037/tgh.2018.07.02. eCollection 2018. Review.

13.

Animal models for cystic fibrosis liver disease (CFLD).

Fiorotto R, Amenduni M, Mariotti V, Cadamuro M, Fabris L, Spirli C, Strazzabosco M.

Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):965-969. doi: 10.1016/j.bbadis.2018.07.026. Epub 2018 Jul 30. Review.

PMID:
30071276
14.

Animal models of cholangiocarcinoma: What they teach us about the human disease.

Cadamuro M, Brivio S, Stecca T, Kaffe E, Mariotti V, Milani C, Fiorotto R, Spirli C, Strazzabosco M, Fabris L.

Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):403-415. doi: 10.1016/j.clinre.2018.04.008. Epub 2018 May 9. Review.

PMID:
29753731
15.

β-Catenin and interleukin-1β-dependent chemokine (C-X-C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis.

Kaffe E, Fiorotto R, Pellegrino F, Mariotti V, Amenduni M, Cadamuro M, Fabris L, Strazzabosco M, Spirli C.

Hepatology. 2018 May;67(5):1903-1919. doi: 10.1002/hep.29652. Epub 2018 Mar 25.

16.

Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.

Brivio S, Cadamuro M, Fabris L, Strazzabosco M.

Gene Expr. 2018 Mar 21;18(1):31-50. doi: 10.3727/105221617X15088670121925. Epub 2017 Oct 25. Review.

17.

Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine.

Carbone M, Cristoferi L, Cortesi PA, Rota M, Ciaccio A, Okolicsanyi S, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Belli LS, Munari LM, Mantovani L, Strazzabosco M.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1415-1422. doi: 10.1016/j.bbadis.2017.08.025. Epub 2017 Aug 24.

18.

Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy.

Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M.

Hepatology. 2018 Mar;67(3):972-988. doi: 10.1002/hep.29400. Epub 2018 Jan 26.

19.

The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.

Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, Strazzabosco M, Fabris L.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1435-1443. doi: 10.1016/j.bbadis.2017.07.028. Epub 2017 Jul 27. Review.

20.

Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium.

Strazzabosco M, Fiorotto R, Cadamuro M, Spirli C, Mariotti V, Kaffe E, Scirpo R, Fabris L.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1374-1379. doi: 10.1016/j.bbadis.2017.07.023. Epub 2017 Jul 25. Review.

Supplemental Content

Loading ...
Support Center